Top stories from TTO's December newsletter:
Xeris Pharma to Develop CU Diabetes Management Drug
Xeris Pharmaceuticals, Inc. (Austin, Texas) and CU recently completed an exclusive license agreement for a jointly-developed method of treating the low blood sugar that is a common side effect of the insulin therapy used to treat many types of diabetes. Hypoglycemia (low blood glucose) can be treated by taking glucose orally, but when a hypoglycemic individual is confused or unconscious, oral glucose may not be an option. In these cases, glucagon (a hormone secreted by the pancreas, like insulin) can be given by injection to quickly raise blood glucose levels; however, glucagon is not stable when dissolved in water, so current injection methods require many extra steps for reconstitution with water before administration. The patent-pending drug reformulation technique developed by CU and Xeris (by a team of researchers led by John Carpenter, a professor at the CU Skaggs School of Pharmacy and Pharmaceutical Sciences, and John Kinzell, CEO of Xeris) provides formulations of glucagon that are shelf-stable and do not require refrigeration, making them faster and more convenient to administer.
Podcast: Colorado Technology Infrastructure and BioFrontiers Institute
W3W3 radio interviewed Jim Linfield, Managing Partner at Cooley LLP and the recipient of TTO's Colorado Technology Infrastructure Leadership Award in 2011. Speaking about CU's newly-launched BioFrontiers Institute (an interdisciplinary center designed to advance transformational biotechnologies), Linfield said: "I think that will solidify CU's position as one of the leading institutions for interdisciplinary research in the life sciences area, covering both therapeutics and diagnostics but also bio fuels, so I think it will be a remarkable institution." Listen to the podcast, or view an archive of all TTO podcasts.
Report Examines Value, Opportunities from Gap Funding of University Technology
Mind the Gap 2011: The University Gap Funding Report examines the role that university-driven gap funding programs play in advancing major innovations. The report begins with an updated version of the university, or early-stage, technology funding landscape. Next, the report looks in-depth at the functionality of 63 gap funding programs across 40 organizations (including CU's proof-of-concept grant program), creating a roadmap for tech transfer managers to develop gap funding programs and presenting benchmarks for policymakers to support these initiatives.
Gilead Strikes Deal with GlobeImmune on Hepatitis B Vaccine
Python Could Help Treat Heart Disease
Read the full newsletter, or sign up to receive a monthly email update.
42 minutes ago